New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.

Abstract:

:Objective tumor responses and survival rates with standard chemotherapy options for small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) have been disappointing. However, several promising new classes of agents have emerged in recent years, including the taxanes, mitotic spindle inhibitors, antimetabolites, and topoisomerase I and II inhibitors. The molecular target of several of these new agents is topoisomerase I, an enzyme that is essential for DNA replication and is up-regulated in tumor cells. Inhibition of this enzyme by drugs such as topotecan and irinotecan leads to cell death and is the basis for their anticancer activity. The process of DNA replication is halted by the covalent binding of the drug in a topoisomerase I drug/DNA ternary reaction intermediate. The pharmacokinetics of the approved regimen--a 30-min infusion daily for 5 days at 21-day intervals--are well defined, with proportional increases in the area under the plasma concentration-time curve, peak plasma concentration, and steady state concentration following application of higher doses. The antitumor activities of both the intravenous and oral formulations of topotecan have been tested in clinical trials. Topotecan is well tolerated and has demonstrated good efficacy in patients with relapsed SCLC when administered as monotherapy or in combination regimens as first-line or second-line therapy. Preliminary trials also indicate that topotecan is well tolerated and has activity in the first-line treatment of NSCLC. In this article an overview of new agents in lung cancer chemotherapy is provided, with particular attention paid to the topoisomerase I inhibitors. A review of topotecan--the first topoisomerase I inhibitor to be approved for second-line therapy in SCLC--is presented as an illustration of the promise these new agents hold for the treatment of SCLC and NSCLC.

journal_name

Oncology

journal_title

Oncology

authors

Huang CH,Treat J

doi

10.1159/000055387

subject

Has Abstract

pub_date

2001-01-01 00:00:00

pages

14-24

eissn

0030-2414

issn

1423-0232

pii

55387

journal_volume

61 Suppl 1

pub_type

杂志文章,评审

相关文献

ONCOLOGY文献大全
  • Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.

    abstract:BACKGROUND AND AIM:In vitro, methotrexate (MTX) is the best modulator for bolus 5-fluorouracil (5FU), whereas folinic acid (FA) is the best for continuous infusion. We evaluated the effect of 5FU modulated by both MTX (bolus administration) and FA (continuous infusion) as second-line treatment of patients with metastat...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000065468

    authors: Carlomagno C,Lauria R,De Laurentiis M,Arpino G,Massarelli E,Ferrara C,Milano A,Vernaglia Lombardi A,Costanzo R,Catalano G,Bianco AR,De Placido S

    更新日期:2002-01-01 00:00:00

  • Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival.

    abstract:OBJECTIVES:Anaplastic oligodendrogliomas (AO) are uncommon primary brain tumors whose natural history, prognosis, and optimal management are not yet fully understood. However, they are associated with a better prognosis and response to multimodality therapy based on specific molecular changes. In this multicenter retro...

    journal_title:Oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1159/000074479

    authors: Puduvalli VK,Hashmi M,McAllister LD,Levin VA,Hess KR,Prados M,Jaeckle KA,Yung WK,Buys SS,Bruner JM,Townsend JJ,Davis R,Sawaya R,Kyritsis AP

    更新日期:2003-01-01 00:00:00

  • 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

    abstract:BACKGROUND:To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA). PATIENTS AND METHODS:We retrospectively analyzed the medical records of 27 patients with MPA treated with FOLFIRINOX ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000329803

    authors: Assaf E,Verlinde-Carvalho M,Delbaldo C,Grenier J,Sellam Z,Pouessel D,Bouaita L,Baumgaertner I,Sobhani I,Tayar C,Paul M,Culine S

    更新日期:2011-01-01 00:00:00

  • Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.

    abstract::Hepatocellular carcinoma (HCC) is common in Asia, and there were no effective chemotherapeutic agents for advanced HCC. Sorafenib, an oral multikinase inhibitor, has set a milestone in the management of HCC in that it is the first agent to significantly improve the overall survival in patients with advanced HCC in a d...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000315246

    authors: Lee JM,Han KH

    更新日期:2010-07-01 00:00:00

  • Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis.

    abstract:OBJECTIVE:The objective of this study was to evaluate the antitumor, survival, and adverse effects of hepatic arterial infusion chemotherapy using epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. METHODS:The study population comprised 45 consecutive patients with advanced...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000112805

    authors: Ikeda M,Okusaka T,Ueno H,Morizane C,Iwasa S,Hagihara A,Kojima Y

    更新日期:2007-01-01 00:00:00

  • Accumulation of 111In-bleomycin in metastatic lesions from carcinoma of the uterine cervix and the ovary.

    abstract::Cases are presented in which 111In-bleomycin accumulated in Virchow's gland metastasis from squamous cell carcinoma of the uterine cervix, and in paratracheal lymphatic gland metastasis from embryonal carcinoma of the right ovary. Thus, this radiopharmaceutical was found to be of great use for assessment of metastatic...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226373

    authors: Kida T,Ikeda M

    更新日期:1986-01-01 00:00:00

  • Gastric non-Hodgkin's lymphoma after successful treatment of Hodgkin's disease.

    abstract::A patient seen at presentation for Hodgkin's disease (HD) at stage IV B was successfully treated with MOPP. In remission he developed coeliac disease, controlled by dietary measures, but 26 months after the end of chemotherapy a severe dyspeptic syndrome appeared; endoscopy and barium meal suggested the presence of a ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226345

    authors: Eridani S,Singh AK

    更新日期:1986-01-01 00:00:00

  • Antiemetic study methodology: recommendations for future studies.

    abstract::The methodology of future antiemetic studies will reflect the need to address the problems identified in current studies. New preclinical information on the mechanisms of emesis and antiemetic action will allow more rational clinical study design. Prior to large randomized studies, phase I and II trials should define ...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000227648

    authors: Olver IN

    更新日期:1996-06-01 00:00:00

  • A case-control study of breast cancer and psychotropic drug use.

    abstract::The relative risk of breast cancer incidence and tumor promotion associated with psychotropic drug consumption was evaluated in 151 patients with newly diagnosed neoplasms and 151 hospital controls. No significantly altered risk of breast cancer was found in association with the use of diazepam, chlordiazepoxide, anti...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225651

    authors: Wallace RB,Sherman BM,Bean JA

    更新日期:1982-01-01 00:00:00

  • Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807).

    abstract:BACKGROUND:Both irinotecan (CPT) and paclitaxel (Pac) are effective against non-small cell lung cancer (NSCLC), and besides, preclinical studies have demonstrated an additive or synergistic interaction between camptothecin and taxane. METHODS:We conducted a phase I/II study of combination chemotherapy consisting of Pa...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000077434

    authors: Yamada K,Ikehara M,Tanaka G,Nomura I,Oshita F,Noda K

    更新日期:2004-01-01 00:00:00

  • Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain.

    abstract:OBJECTIVES:A novel delivery system for transdermal matrix patches of fentanyl has been developed. The new fentanyl tape consists of a backing layer, a drug-containing layer and a release liner that is originally made of rubber adhesive. This open-label prospective study investigated the pharmacokinetics and safety of t...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000356625

    authors: Saito T,Fujii M,Saito S,Shimada K,Fujiwara K,Kobayashi K

    更新日期:2014-01-01 00:00:00

  • Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts.

    abstract::As TS-1 and docetaxel (TXT) have different mechanisms of antitumor activity, the combination therapy is expected to have a higher response. Human gastric cancer xenografts SC-2, St-40, and SC-4 inoculated into nude rats were treated with TS-1 alone (TS-1 12 mg/kg/day, day 1-14), TXT alone (TXT 2 mg/kg/day, day 1 or da...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000086767

    authors: Takahashi I,Emi Y,Kakeji Y,Uchida J,Fukushima M,Maehara Y

    更新日期:2005-01-01 00:00:00

  • A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.

    abstract:PURPOSE:In order to broaden the possibility for anti-MAGE-3 immune targeting, it is important to identify HLA-A24-restricted epitopes derived from MAGE-3, since HLA-A24 is one of the most common alleles in Japanese and Asian people. In the present study, we defined a new MAGE-3 derived, HLA-A24-binding peptide presente...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000091185

    authors: Miyagawa N,Kono K,Mimura K,Omata H,Sugai H,Fujii H

    更新日期:2006-01-01 00:00:00

  • Progress of cancer pain management in Korea.

    abstract::Cancer pain management had received relatively little attention until the late 1990s, when approximately 100,000 new cancer cases and 60,000 cancer deaths occurred each year in Korea. In 2001, a Cancer Pain Management Guideline was prepared for the first time by the Korean Society of Hospice and Palliative Care. This ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000143211

    authors: Lee JY,Ahn JS

    更新日期:2008-01-01 00:00:00

  • Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers.

    abstract:OBJECTIVE:ETS-1 has been identified as a proto-oncogene and a transcription factor for tumor angiogenesis, which is essential for the growth, invasion and metastasis of solid tumors. The aim is to investigate the clinical implications of ETS-1 expression in peritoneal metastatic lesions of ovarian cancers. METHODS:In ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000079491

    authors: Fujimoto J,Aoki I,Toyoki H,Khatun S,Sato E,Sakaguchi H,Tamaya T

    更新日期:2004-01-01 00:00:00

  • Differences in cellular proteins between high and low metastatic potential sublines from the methylcholanthrene-induced rat fibrosarcoma cell line.

    abstract::The purpose of the present study was to determine with two-dimensional electrophoresis whether two sublines (high and low metastatic potential to lymph nodes) of rat fibrosarcoma induced by methylcholanthrene have differences in cellular proteins. The high metastatic potential subline had a specific protein in the pro...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000227028

    authors: Minato K,Manabe T,Okuyama N,Sasaki Y,Nakagawa K,Saijo N

    更新日期:1992-01-01 00:00:00

  • Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.

    abstract:OBJECTIVE:To report the outcomes of surgical resection of borderline resectable (BL) and locally advanced (LA) 'unresectable' pancreatic cancer after neoadjuvant chemotherapy. METHODS:A review of a prospectively maintained database for pancreatic resections was undertaken to identify patients undergoing resection for ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000371745

    authors: Addeo P,Rosso E,Fuchshuber P,Oussoultzoglou E,De Blasi V,Simone G,Belletier C,Dufour P,Bachellier P

    更新日期:2015-01-01 00:00:00

  • High-dose chemotherapy and autologous hematopoietic stem cell transplantation: the lymphoma experience and its potential relevance to solid tumors.

    abstract::Lymphomas, which are frequently subdivided into Hodgkin's disease and non-Hodgkin's lymphoma, represent one of the more curable cancers that present as a solid tumor. Unfortunately, most patients cannot be cured with conventional chemotherapy, therefore new techniques have been developed including high-dose chemothera...

    journal_title:Oncology

    pub_type: 杂志文章,评审

    doi:10.1159/000012100

    authors: Armitage JO

    更新日期:2000-04-01 00:00:00

  • Risk factors of metastasis in oral squamous cell carcinomas.

    abstract::Lymph node and distant metastasis were comparatively studied in 225 oral carcinomas, and factors predisposing toward metastasis were investigated using clinical and immunohistopathological approaches. Neither the sites of tumors nor T-stage was correlated with either type of metastasis. Tumor cell differentiation was ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000012090

    authors: Osaki T,Kimura T,Tatemoto Y,Yamamoto T,Yoneda K

    更新日期:2000-02-01 00:00:00

  • Efficacy of Vinorelbine Monotherapy as Third- or Further-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.

    abstract:BACKGROUND:The survival rate of patients with lung cancer has increased significantly over the years, but there has been no further progress in third- or fourth-line therapy. We investigated the efficacy and tolerability of monotherapy with weekly vinorelbine, a semi-synthetic vinca alkaloid, in advanced non-small-cell...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000502343

    authors: Kang DH,Kim JO,Jung SS,Park HS,Chung C,Park D,Lee JE

    更新日期:2019-01-01 00:00:00

  • The squamous cell carcinoma tumor marker in mammary carcinoma: comparison of polyclonal versus monoclonal antibody-based assays.

    abstract::Pretreatment serum levels of squamous cell carcinoma (SCC)-antigen as determined with a polyclonal and monoclonal antibody-based assay were determined in 136 patients with invasive mammary carcinoma, 8 patients with ductal carcinoma in situ and 23 patients with benign breast diseases. For the polyclonal assay, the ove...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000226778

    authors: Wobbes T,Thomas CM,Segers MF

    更新日期:1990-01-01 00:00:00

  • Defective expression of HRK is associated with promoter methylation in primary central nervous system lymphomas.

    abstract:OBJECTIVES:Recently, it has been reported that expression of the HRK gene was significantly reduced by hypermethylation in astrocytic tumors. Our aim is to verify the alterations in the HRK gene in primary central nervous system lymphomas (PCNSLs). METHODS:We analyzed the hypermethylation status and expression of the ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000094322

    authors: Nakamura M,Ishida E,Shimada K,Nakase H,Sakaki T,Konishi N

    更新日期:2006-01-01 00:00:00

  • Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.

    abstract:OBJECTIVES:Suboptimal debulking (>1 cm residual tumor) results in poor survival rates for patients with an advanced stage of ovarian cancer. The purpose of this study was to develop a prediction model, based on simple preoperative parameters, for patients with an advanced stage of ovarian cancer who are at risk of subo...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000113051

    authors: de Jong D,Eijkemans MJ,Lie Fong S,Gerestein CG,Kooi GS,Baalbergen A,van der Burg ME,Burger CW,Ansink AC

    更新日期:2007-01-01 00:00:00

  • Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.

    abstract:OBJECTIVES:Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, ...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000487266

    authors: Vincenzi B,Badalamenti G,Armento G,Silletta M,Spalato Ceruso M,Catania G,Napolitano A,Maltese G,Valeri S,Incorvaia L,Santini D,Tonini G

    更新日期:2018-01-01 00:00:00

  • Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.

    abstract:OBJECTIVES:This study aimed to evaluate any correlations between baseline creatinine clearance and the development of grade 3/4 toxicities during treatment within oncology phase I trials of molecularly targeted agents where entry criteria mandate a serum creatinine of ≤ 1.5 × the upper limit of normal. METHODS:Documen...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000341152

    authors: Basu B,Vitfell-Pedersen J,Moreno Garcia V,Puglisi M,Tjokrowidjaja A,Shah K,Malvankar S,Anghan B,de Bono JS,Kaye SB,Molife LR,Banerji U

    更新日期:2012-01-01 00:00:00

  • Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.

    abstract:OBJECTIVE:BRAF D594G mutations in colorectal cancer patients are not clearly understood. We retrospectively investigated the clinicopathological features of colorectal cancers with BRAF D594G mutations. METHODS:We selected 908 colorectal cancer patients who underwent surgical resection from January 2008 to January 201...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000447402

    authors: Amaki-Takao M,Yamaguchi T,Natsume S,Iijima T,Wakaume R,Takahashi K,Matsumoto H,Miyaki M

    更新日期:2016-01-01 00:00:00

  • Less Fibrotic Burden Differently Affects the Long-Term Outcomes of Hepatocellular Carcinoma after Curative Resection.

    abstract:BACKGROUND:The clinical features of hepatocellular carcinoma (HCC) differ in patients with and without cirrhosis. OBJECTIVE:We aimed to investigate the long-term outcomes of noncirrhotic HCC patients after curative resection. METHODS:We retrospectively examined 649 consecutive patients with HCC who underwent curative...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000477173

    authors: Lee HW,Choi GH,Kim DY,Park YN,Kim KS,Choi JS,Ahn SH,Han KH

    更新日期:2017-01-01 00:00:00

  • Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.

    abstract:OBJECTIVE:The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxaliplatin (FOLFOX) regimens in clinical practice according to their efficacy and toxicity. METHODS:Patients who received oxaliplatin-containing regimens after curative resection for colorectal carcinoma from 10 different o...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1159/000336902

    authors: Uncu D,Aksoy S,Çetin B,Yetişyiğit T,Özdemir N,Berk V,Dane F,Inal A,Harputluoğlu H,Budakoğlu B,Koca D,Sevinç A,Cihan S,Durnalı AG,Özkan M,Öztürk MA,Işıkdoğan A,Büyükberber S,Benekli M,Köş T,Alkış N,Karaca H,Tur

    更新日期:2013-01-01 00:00:00

  • Gemcitabine and cisplatin in refractory malignant lymphoma.

    abstract:OBJECTIVE:We performed a pilot study to evaluate the effect of the high-dose gemcitabine-cisplatin combination in a brief weekly regimen in the treatment of primary refractory diffuse large cell lymphoma with high or high-intermediate clinical risk. METHODS:Thirty patients refractory to first-line anthracycline-based ...

    journal_title:Oncology

    pub_type: 临床试验,杂志文章

    doi:10.1159/000077995

    authors: Avilés A,Neri N,Huerta-Guzmán J,Fernández R

    更新日期:2004-01-01 00:00:00

  • Heritable colonic cancer syndromes: induction of anchorage-independence in dermal cultures derived from patients with adenomatosis of the colon and rectum.

    abstract::After exposure to the mutagen, ethylmethanesulfonate (EMS), or the carcinogen, urethane (UR), anchorage independence was observed in cultures derived from normal skin biopsies from patients with the heritable cancer syndrome, adenomatosis of the colon and rectum (ACR). Such colonies from methylcellulose suspension cul...

    journal_title:Oncology

    pub_type: 杂志文章

    doi:10.1159/000225478

    authors: Danes BS

    更新日期:1980-01-01 00:00:00